Hyaluronic acid in the evaluation of liver fibrosis in patients with hepatitis C on haemodialysis

• Autor(a) principal: Ávila,Renata Eliane de
• Data de Publicação: 2010
• Outros Autores: Carmo,Ricardo Andrade, Farah,Kátia de Paula, Teixeira,Antônio Lúcio, Coimbra,Lucas Viana, Antunes,Carlos Maurício de Figueiredo, Lambertucci,José Roberto
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Brazilian Journal of Infectious Diseases
• Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702010000400004
• topic: liver fibrosis; hyaluronic acid; end-stage renal disease; haemodialysis; hepatitis C

BACKGROUND: This study evaluated the role of HA as a marker of liver fibrosis in patients with hepatitis C on haemodialysis. METHODS: This is a cross-sectional study in which 52 patients were divided into two groups: Group 1: patients with hepatitis C and end-stage renal disease (ESRD) undergoing haemodialysis (n = 23); and Group 2: patients with hepatitis C without ESRD (n = 29). Plasma levels of HA were associated with histological data of the samples obtained by liver biopsy and classified by METAVIR group scoring system. RESULTS: Higher plasma levels were significantly correlated to significant liver fibrosis (METAVIR > F2). In Group 1, the HA cutoff to discriminate significant fibrosis was 984.8 ng/mL, with accuracy, sensitivity and specificity of 80.8%, 83.0%, and 70.0%, respectively. In Group 2, the HA cutoff was 222.3 ng/mL, with accuracy, sensitivity and specificity of 74.5%, 70.0%, and 94.0%, respectively. CONCLUSION: HA was an accurate noninvasive marker in predicting significant fibrosis in patients with hepatitis C on haemodialysis.